The Theranostic Genome.

Autor: Xu X; University of Lucerne, Lucerne, LU, Switzerland., Jané P; University of Geneva, Geneva, GE, Switzerland.; Nuclear Medicine and Molecular Imaging Division, Geneva University Hospitals, Geneva, GE, Switzerland., Taelman V; University of Lucerne, Lucerne, LU, Switzerland., Jané E; Departamento de Matemática Aplicada a la Ingeniería Aeroespacial - ETSIAE, Universidad Politécnica de Madrid, 28040, Madrid, Spain., Dumont RA; University of Lucerne, Lucerne, LU, Switzerland., Garama Y; University of Lucerne, Lucerne, LU, Switzerland., Kim F; University of Lucerne, Lucerne, LU, Switzerland., Del Val Gómez M; Servicio de Medicina Nuclear, Hospital Universitario Ramón y Cajal, Madrid, Spain., Gariani K; Division of Endocrinology, Diabetes, Nutrition and Patient Therapeutic Education, Geneva University Hospitals, Geneva, GE, Switzerland., Walter MA; University of Lucerne, Lucerne, LU, Switzerland. martin.alexander.walter@gmail.com.; St. Anna Hospital, University of Lucerne, Lucerne, LU, Switzerland. martin.alexander.walter@gmail.com.
Jazyk: angličtina
Zdroj: Nature communications [Nat Commun] 2024 Dec 30; Vol. 15 (1), pp. 10904. Date of Electronic Publication: 2024 Dec 30.
DOI: 10.1038/s41467-024-55291-x
Abstrakt: Theranostic drugs represent an emerging path to deliver on the promise of precision medicine. However, bottlenecks remain in characterizing theranostic targets, identifying theranostic lead compounds, and tailoring theranostic drugs. To overcome these bottlenecks, we present the Theranostic Genome, the part of the human genome whose expression can be utilized to combine therapeutic and diagnostic applications. Using a deep learning-based hybrid human-AI pipeline that cross-references PubMed, the Gene Expression Omnibus, DisGeNET, The Cancer Genome Atlas and the NIH Molecular Imaging and Contrast Agent Database, we bridge individual genes in human cancers with respective theranostic compounds. Cross-referencing the Theranostic Genome with RNAseq data from over 17'000 human tissues identifies theranostic targets and lead compounds for various human cancers, and allows tailoring targeted theranostics to relevant cancer subpopulations. We expect the Theranostic Genome to facilitate the development of new targeted theranostics to better diagnose, understand, treat, and monitor a variety of human cancers.
Competing Interests: Competing interests: The authors declare no competing interests.
(© 2024. The Author(s).)
Databáze: MEDLINE
Externí odkaz: